IVF

INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.

Wall Street analysts forecast IVF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVF is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

INVO Fertility Inc revenue for the last quarter amounts to 1.76M USD, increased 22.60 % YoY.

INVO Fertility Inc. EPS for the last quarter amounts to -6.14 USD, decreased -94.92 % YoY.

INVO Fertility Inc (IVF) has 28 emplpoyees as of December 15 2025.

Today IVF has the market capitalization of 3.20M USD.